Abstract 1935P
Background
The tertiary lymphoid structure (TLS) is an important part of the tumor microenvironment. It generates circulating immune cells and inhibits tumor growth and progression, which is closely related to the efficacy of immunotherapy.
Methods
This study collected the transcriptome information and clinical data of 10327 tumor samples and 730 normal samples of 33 cancer types from the TCGA database. Based on previous literature, three sets of TLS-related gene sets were selected and merged into the total TLS gene set. The TLS enrichment scores were calculated by the GSVA algorithm. Further, utilize TIMER 2.0 and CIBERSORTNE algorithms to analyze the distribution of tumor-infiltrating immune cells. Based on the enrichment score of TLS, sarcoma patients were divided into three TLS subtypes via the "hclust" R package. TLS-related prognostic core genes were screened via Lasso Cox and multivariate Cox regression and further used to establish the TLS-related prognostic signature. The public immunotherapy cohorts and our center immunotherapy patients were used to validate the efficacy of immunotherapy.
Results
The TLS gene set enrichment score established in this study is significantly positively correlated with immune cell infiltration such as T cells, B cells, and DC cells, which can reflect the TLS status in tumor tissue. Kaplan Meier survival analysis showed that patients with high TLS had better overall survival and progression-free survival compared to patients with low TLS. Through Lasso Cox and multivariate Cox regression, two TLS-related prognostic core genes (TNFRSF14 and DUSP9) were ultimately screened, and a TLS-related prognostic signature was established. Immunohistochemistry showed that the expression of TNFRSF14 was increased and the expression of DUSP9 was reduced in patients with soft tissue sarcoma who achieved optimal immunotherapy.
Conclusions
The TLS-Total gene set, TLS-related prognostic signature, TNFRSF14, and DUSP9 selected in this study can predict the prognosis of patients with soft tissue sarcoma. TNFRSF14 and DUSP9 are associated with immune cell infiltration, which can indicate the efficacy of immunotherapy and may become new predictive markers of immunotherapy efficacy.
Clinical trial identification
No
Editorial acknowledgement
No
Legal entity responsible for the study
The authors.
Funding
Natural Science Basic Research Program of Shaanxi (No. 2021JZ-35).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15